Arrowhead Pharmaceuticals Inc. (ARWR)
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARWR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.85B
- EPS (TTM)
- -$5.11
- Dividend yield
- None
- 52-week range
- 40.43 – 95.49
- Day range
- 41.17 – 44.80
- Volume / Avg
- 3.91M / 2.08M
- Beta
- —
- Shares outstanding
- 141.37M
- Next earnings
- Nov 24, 2026
52-week range
ARWR stock today
Arrowhead Pharmaceuticals (ARWR) closed at $41.37 on Nov 20, down 5.22% (-$2.28), versus the S&P 500's 3.70% decline. At this level, ARWR sits near the bottom of its 52-week range of $40.43 to $95.49: 56.7% below the high, set on Jul 22, 2026 and 2.3% above the low. ARWR is down 37.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 2.3%.
Arrowhead Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$5.11), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 24; analysts expect EPS of -$1.59.
Summary generated from market data by MetaCap's automated system. Methodology
About Arrowhead Pharmaceuticals
Company profileArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Christopher R. Anzalone Ph.D.
- Headquarters
- Pasadena, CA
- Employees
- 1,062
- Website
- arrowheadpharma.com
Financial highlights
Full financialsIn fiscal 2026, Arrowhead Pharmaceuticals generated $450.8 million in revenue, down 45.6% from fiscal 2025, its first annual decline since 2024. Arrowhead Pharmaceuticals reported a net loss of $724.2 million, compared with a loss of $1.6 million a year earlier. Operating margin was -156.9%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $450.82M | $829.45M | $3.55M | $240.74M | $243.23M |
| Growth | -45.65% | +23258.15% | -98.52% | -1.03% | +75.89% |
| Net income | $-724.21M | $-1.63M | $-599.49M | $-205.28M | $-176.06M |
| EPS (diluted) | $-5.11 | $-0.01 | $-5.00 | $-1.92 | $-1.67 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$106.07+156.39%
- Strong buy 4
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 24, 2026
- EPS estimate
- $-1.59
- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-3.04 vs $-1.59
- Surprise
- -91.19%
ARWR news
All ARWR news- Arrowhead Pharmaceuticals, Inc. Reports Fiscal 2026 Results and Announces $400 million RefinancingNasdaq
- Arrowhead (ARWR) Q4 2026 Earnings Call TranscriptNasdaqARWR, WSO.B
- Arrowhead Pharmaceuticals GAAP EPS of -$5.11 misses by $1.51, revenue of $450.82M misses by $13.32MSeeking Alpha
- Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End ResultsBusiness Wire
- Arrowhead Pharmaceuticals FY 2026 Earnings PreviewSeeking Alpha
- Arrowhead Pharmaceuticals Becomes Oversold (ARWR)Nasdaq
- Arrowhead Pharmaceuticals options signal 8.1% move on earningsInvesting.com
- Arrowhead Pharmaceuticals, Inc. Refinances Senior Secured Term Loans with $400.0 million Credit FacilityNasdaq
Arrowhead Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SUPNSupernus Inc. | 28.61 | +0.92% | $5.94B | vs ARWR |
| LGNDLigand Pharmaceuticals Incorporated | 286.85 | -0.03% | $5.74B | vs ARWR |
| GRFSGrifols S.A. ADR | 8.15 | -0.61% | $5.55B | vs ARWR |
| MIRMMirum Pharmaceuticals Inc. | 96.13 | +0.65% | $6.28B | vs ARWR |
| ABVXAbivax SA ADR | 73.20 | -9.24% | $6.41B | vs ARWR |
| BLTEBelite Bio Inc ADR | 127.38 | -15.65% | $5.17B | vs ARWR |
| MANEVeradermics Incorporated | 119.52 | -3.92% | $5.04B | vs ARWR |
| LQDALiquidia Corporation | 54.43 | -3.88% | $4.90B | vs ARWR |
Indexes, lists and sector
Arrowhead Pharmaceuticals stock FAQ
What is Arrowhead Pharmaceuticals's stock price today?
ARWR last traded at $41.37 as of Nov 20, 4:00 PM EST, down 5.22% on the day. Prices are delayed at least 15 minutes.
Does Arrowhead Pharmaceuticals pay a dividend?
No. Arrowhead Pharmaceuticals does not currently pay a regular cash dividend.
When is Arrowhead Pharmaceuticals's next earnings date?
Arrowhead Pharmaceuticals is expected to report earnings on Tuesday, November 24, 2026. Analysts expect EPS of $-1.59.
Who is Arrowhead Pharmaceuticals's CEO?
Dr. Christopher R. Anzalone Ph.D. is the chief executive officer of Arrowhead Pharmaceuticals Inc., which has about 1,062 employees.
Has ARWR ever split its stock?
Yes. The most recent ARWR stock split was a 1-for-10 split on Nov 17, 2011, one of 2 splits on record.
What is the ARWR 52-week high?
The 52-week high for ARWR is $95.49 and the 52-week low is $40.43. The stock is currently 56.7% below its high.